Correction: Kazia is entering a phase 2 Agile trial sometime next year. If (and only if) the phase 2 is completed successfully the Phase 3 sequential trial can commence. Completion is expected in two to three years. This is specified in the "clinical trail summary" which can be found on the Kazia website and associated ASX announcement.
KZA Price at posting:
$1.38 Sentiment: None Disclosure: Not Held